Literature DB >> 17658575

High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Qinxue Hu1, Naheed Mahmood, Robin J Shattock.   

Abstract

HIV-1 uses glycans on gp120 to occlude its highly immunogenic epitopes. To better elucidate escape mechanisms of HIV-1 from carbohydrate-binding agents (CBA) and to understand the impact of CBA-escape on viral immune evasion, we generated and examined the biological properties of HIV-1 resistant to cyanovirin-N (CV-N) or cross-resistant to additional CBAs. Genotypic and phenotypic characterization of resistant env clones indicated that 3-5 high-mannose residues from 289 to 448 in the C2-C4 region of gp120 were mutated and correlated with the resistance levels. The specificity and minimal requirements of deglycosylation for CV-N resistance were further assessed by mutagenesis study. The sensitivity of resistant variants to a range of CBAs, immunoglobulins, sera and monoclonal antibodies (MAb) were investigated. For the first time, our data have collectively defined the high-mannose residues on gp120 affecting CV-N activity, and demonstrated that CBA-escape HIV-1 has increased sensitivity to immunoglobulins and sera from HIV patients, and particularly to V3 loop-directed MAbs. Our study provides a proof-of-concept that targeting HIV-1 glycan shields may represent a novel antiviral strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658575      PMCID: PMC2121147          DOI: 10.1016/j.virol.2007.06.029

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV.

Authors:  Jan Balzarini
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

2.  Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.

Authors:  Toshiyuki Mori; Barry R O'Keefe; Raymond C Sowder; Scott Bringans; Roberta Gardella; Shannon Berg; Pamela Cochran; Jim A Turpin; Robert W Buckheit; James B McMahon; Michael R Boyd
Journal:  J Biol Chem       Date:  2004-12-21       Impact factor: 5.157

3.  Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.

Authors:  Qinxue Hu; Kelby B Napier; John O Trent; Zixuan Wang; Stephen Taylor; George E Griffin; Stephen C Peiper; Robin J Shattock
Journal:  J Mol Biol       Date:  2005-07-22       Impact factor: 5.469

Review 4.  The C-type lectin superfamily in the immune system.

Authors:  W I Weis; M E Taylor; K Drickamer
Journal:  Immunol Rev       Date:  1998-06       Impact factor: 12.988

5.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

Authors:  Ronald S Veazey; Per Johan Klasse; Susan M Schader; Qinxue Hu; Thomas J Ketas; Min Lu; Preston A Marx; Jason Dufour; Richard J Colonno; Robin J Shattock; Martin S Springer; John P Moore
Journal:  Nature       Date:  2005-10-30       Impact factor: 49.962

6.  Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.

Authors:  Sang-Moo Kang; Fu Shi Quan; Chunzi Huang; Lizheng Guo; Ling Ye; Chinglai Yang; Richard W Compans
Journal:  Virology       Date:  2005-01-05       Impact factor: 3.616

7.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 8.  Proteins that bind high-mannose sugars of the HIV envelope.

Authors:  Istvan Botos; Alexander Wlodawer
Journal:  Prog Biophys Mol Biol       Date:  2005-06       Impact factor: 3.667

9.  The rational design of an AIDS vaccine.

Authors:  Daniel C Douek; Peter D Kwong; Gary J Nabel
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

10.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

View more
  33 in total

1.  The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.

Authors:  Katrien O François; Jan Balzarini
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

Review 2.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

3.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

4.  Rhizosecretion improves the production of Cyanovirin-N in Nicotiana tabacum through simplified downstream processing.

Authors:  Julian K-C Ma; Pascal M W Drake; Luisa M Madeira; Tim H Szeto
Journal:  Biotechnol J       Date:  2016-03-09       Impact factor: 4.677

5.  Carbohydrate recognition by the antiviral lectin cyanovirin-N.

Authors:  Yukiji K Fujimoto; David F Green
Journal:  J Am Chem Soc       Date:  2012-11-20       Impact factor: 15.419

6.  Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Authors:  Kabamba B Alexandre; Elin S Gray; Bronwen E Lambson; Penny L Moore; Isaac A Choge; Koleka Mlisana; Salim S Abdool Karim; James McMahon; Barry O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2010-04-13       Impact factor: 3.616

7.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

8.  Solution and crystal molecular dynamics simulation study of m4-cyanovirin-N mutants complexed with di-mannose.

Authors:  Ivan I Vorontsov; Osamu Miyashita
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

9.  Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.

Authors:  Kurt Vermeire; Kristel Van Laethem; Wouter Janssens; Thomas W Bell; Dominique Schols
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

10.  A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.

Authors:  Robert J Luallen; Hu Fu; Caroline Agrawal-Gamse; Innocent Mboudjeka; Wei Huang; Fang-Hua Lee; Lai-Xi Wang; Robert W Doms; Yu Geng
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.